Carregando…
COGT
Cogent Biosciences, Inc.
NASDAQ· Healthcare· Biotechnology
$34.67-6.52%
Indicadores
- Market cap
- $6.02B
- P/L
- —
- P/L projetado
- —
- P/VP
- 12.7x
- Dividend yield
- —
- EPS
- -$2.02
- ROE
- -109.74%
- Margem líquida
- 0.00%
- Crescimento de receita
- —
- Beta
- 0.33
- Máxima 52 semanas
- $43.73
- Mínima 52 semanas
- $11.60
Histórico
Como a empresa evoluiu, ano a ano. Receita e dívida vêm dos demonstrativos anuais; os dividendos, dos próprios pagamentos, que alcançam mais anos.
As barras são um saldo na data de fechamento; as linhas são o que aconteceu ao longo do ano. Receita acima do patrimônio é o normal, não anomalia — significa que a empresa gira o capital mais de uma vez por ano.
Investidores posicionados
Grandes gestores que reportaram esta ação no 13F mais recente.
Sobre a empresa
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
- 258
- Waltham, United States
Descrição da empresa fornecida pelo Yahoo Finance. A descrição é publicada pela fonte apenas em inglês.